ProQR Therapeutics (PRQR) Stock Price, News & Analysis

Company Overview

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Key Stats

• Today's Range: $1.53 to $1.64
• 50-Day Range: $1.12 to $2.58
• 52-Week Range: $1.07 to $4.62
• Volume: 251,565 shs
• Average Volume: 596,654 shs
• Market Capitalization: $169.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.50
• Consensus Rating: Buy

ProQR Therapeutics Stock Analysis - MarketRank™

ProQR Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 786th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

ProQR Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ProQR Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.31) to ($0.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ProQR Therapeutics is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ProQR Therapeutics is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ProQR Therapeutics has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.10% of the float of ProQR Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

ProQR Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ProQR Therapeutics has recently decreased by 2.09%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ProQR Therapeutics does not currently pay a dividend.

Dividend Growth

ProQR Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.10% of the float of ProQR Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

ProQR Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ProQR Therapeutics has recently decreased by 2.09%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.38

News Sentiment

ProQR Therapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for ProQR Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added ProQR Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.40% of the stock of ProQR Therapeutics is held by insiders.

Percentage Held by Institutions

Only 32.65% of the stock of ProQR Therapeutics is held by institutions.

PRQR Stock Analysis - Frequently Asked Questions

How have PRQR shares performed this year?

ProQR Therapeutics' stock was trading at $2.65 at the beginning of the year. Since then, PRQR stock has decreased by 41.9% and is now trading at $1.54.
View the best growth stocks for 2025 here.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) posted its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.01. The biopharmaceutical company had revenue of $4.22 million for the quarter, compared to the consensus estimate of $4.75 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 71.58% and a negative net margin of 134.31%.

Who are ProQR Therapeutics' major shareholders?

Top institutional investors of ProQR Therapeutics include Vontobel Holding Ltd. (0.03%).

How do I buy shares of ProQR Therapeutics?

Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ProQR Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), (BIOA) (BIOA) and Virgin Galactic (SPCE).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 4/29/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRQR
• CIK: 1612940
• Web: www.proqr.com
• Phone: (188) 166-7000
• Fax: N/A
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.50
• High Stock Price Target: $15.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +516.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-30,430,000.00
• Net Margins: -134.31%
• Pretax Margin: -135.46%
• Return on Equity: -71.58%
• Return on Assets: -19.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.33
• Quick Ratio: 2.33

Sales & Book Value

• Annual Sales: $18.91 million
• Price / Sales: 8.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.55 per share
• Price / Book: 2.80

Miscellaneous

• Outstanding Shares: 105,213,000
• Free Float: 74,819,000
• Market Cap: $162.03 million
• Optionable: Optionable
• Beta: 0.25